We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Collaboration for Genomic-Based Prospective Medicine

By Biotechdaily staff writers
Posted on 11 Jun 2003
A formal collaboration to create the first fully integrated, comprehensive practice of genomic-based prospective medicine has been announced by the Center for the Advancement of Genomics (TCAG, Rockville, MD, USA) and Duke University Medical Center (Durham, NC, USA). More...
The two groups will work together, utilizing correlations between comprehensive genomic and medical data relevant to prediction, early detection, and prevention of disease.

Plans call for focused research in genomic predictors of cardiovascular, hematologic, and infectious diseases; the design of future clinical practice models, including personalized health planning; and strategies to tackle ethical and legal issues that will arise as a result of advances in genomics. Detailed planning is now under way. Specific goals include the following: to integrate high-throughput DNA sequencing and analysis with medical expertise by re-sequencing and genotyping selected patients from Duke Medical Center, to focus initially on major disease areas as well as cancer, to create a futuristic personalized health plan and medical record, and to leverage the high-end computing center TCAG is building that will allow the sequencing of 45 billion base pairs of DNA per year.

"One of my reasons for wanting to sequence the human genome more rapidly was to get to this point in history where genomics could begin to be used to better understand and potentially treat or prevent human disease,” said J. Craig Venter, Ph.D., president and chairman of TCAG.

"The current American health care system is driven more by tradition than by scientific principles and is inherently wasteful,” remarked R. Sanders Williams, M.D., dean of the Duke University School of Medicine. "By incorporating scientific advances, such as genomics, into new models of prospective health care delivery, we can improve outcomes while controlling costs.”




Related Links:
Center for the Advancement of Genomics
Duke Med. Center

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ESR Analyzer
miniiSED™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.